Temozolomide Teva

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
18-02-2022
Karakteristik produk Karakteristik produk (SPC)
18-02-2022

Bahan aktif:

temozolomide

Tersedia dari:

Teva B.V. 

Kode ATC:

L01AX03

INN (Nama Internasional):

temozolomide

Kelompok Terapi:

Antineoplastic agents

Area terapi:

Glioma; Glioblastoma

Indikasi Terapi:

For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

Ringkasan produk:

Revision: 21

Status otorisasi:

Authorised

Tanggal Otorisasi:

2010-01-28

Selebaran informasi

                                47
B. PACKAGE LEAFLET
48
PACKAGE LEAFLET: INFORMATION FOR THE USER
TEMOZOLOMIDE TEVA 5 MG HARD CAPSULES
TEMOZOLOMIDE TEVA 20 MG HARD CAPSULES
TEMOZOLOMIDE TEVA 100 MG HARD CAPSULES
TEMOZOLOMIDE TEVA 140 MG HARD CAPSULES
TEMOZOLOMIDE TEVA 180 MG HARD CAPSULES
TEMOZOLOMIDE TEVA 250 MG HARD CAPSULES
temozolomide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Temozolomide Teva is and what it is used for
2.
What you need to know before you take Temozolomide Teva
3.
How to take Temozolomide Teva
4.
Possible side effects
5.
How to store Temozolomide Teva
6.
Contents of the pack and other information
1.
WHAT TEMOZOLOMIDE TEVA IS AND WHAT IT IS USED FOR
Temozolomide Teva contains a medicine called temozolomide. This
medicine is an antitumour agent.
Temozolomide Teva is used for the treatment of specific forms of brain
tumours:
-
in adults with newly-diagnosed glioblastoma multiforme. Temozolomide
Teva is first used
together with radiotherapy (concomitant phase of treatment) and after
that alone (monotherapy
phase of treatment).
-
in children 3 years and older and adult patients with malignant
glioma, such as glioblastoma
multiforme or anaplastic astrocytoma. Temozolomide Teva is used in
these tumours if they
return or get worse after standard treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE TEMOZOLOMIDE TEVA
DO NOT TAKE TEMOZOLOMIDE TEVA
-
if you are allergic to temozolomide or any of the other ingredients of
this medicine (listed in
section 6).
-
if you have had an allergic reaction to
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Temozolomide Teva 5 mg hard capsules
Temozolomide Teva 20 mg hard capsules
Temozolomide Teva 100 mg hard capsules
Temozolomide Teva 140 mg hard capsules
Temozolomide Teva 180 mg hard capsules
Temozolomide Teva 250 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Temozolomide Teva 5 mg hard capsules
Each hard capsule contains 5 mg temozolomide.
_Excipient with known effect _
Each hard capsule contains 87 mg of lactose.
Temozolomide Teva 20 mg hard capsules
Each hard capsule contains 20 mg temozolomide.
_Excipients with known effect _
Each hard capsule contains 72 mg of lactose and sunset yellow FCF
(E110).
Temozolomide Teva 100 mg hard capsules
Each hard capsule contains 100 mg temozolomide.
_Excipient with known effect _
Each hard capsule contains 84 mg of lactose.
Temozolomide Teva 140 mg hard capsules
Each hard capsule contains 140 mg temozolomide.
_Excipient with known effect _
Each hard capsule contains 117 mg of lactose.
Temozolomide Teva 180 mg hard capsules
Each hard capsule contains 180 mg temozolomide.
_Excipient with known effect _
Each hard capsule contains 150 mg of lactose.
Temozolomide Teva 250 mg hard capsules
Each hard capsule contains 250 mg temozolomide.
_Excipient with known effect _
Each hard capsule contains 209 mg of lactose.
For the full list of excipients, see section 6.1.
3
3.
PHARMACEUTICAL FORM
Hard capsule.
Temozolomide Teva 5 mg hard capsules
The hard capsules have a white opaque body and cap with two stripes in
green ink on the cap and with
“T 5 mg” in green ink on the body. Each capsule is approximately
16 mm in length.
Temozolomide Teva 20 mg hard capsules
The hard capsules have a white opaque body and cap with two stripes in
orange ink on the cap and
with “T 20 mg” in orange ink on the body. Each capsule is
approximately 18 mm in length.
Temozolomide Teva 100 mg hard capsules
The hard capsules have a white opaque body and cap with two stripes in
pink ink on the cap and with
“T 100
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 18-02-2022
Karakteristik produk Karakteristik produk Bulgar 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Bulgar 18-09-2014
Selebaran informasi Selebaran informasi Spanyol 18-02-2022
Karakteristik produk Karakteristik produk Spanyol 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Spanyol 18-09-2014
Selebaran informasi Selebaran informasi Cheska 18-02-2022
Karakteristik produk Karakteristik produk Cheska 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Cheska 18-09-2014
Selebaran informasi Selebaran informasi Dansk 18-02-2022
Karakteristik produk Karakteristik produk Dansk 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Dansk 18-09-2014
Selebaran informasi Selebaran informasi Jerman 18-02-2022
Karakteristik produk Karakteristik produk Jerman 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Jerman 18-09-2014
Selebaran informasi Selebaran informasi Esti 18-02-2022
Karakteristik produk Karakteristik produk Esti 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Esti 18-09-2014
Selebaran informasi Selebaran informasi Yunani 18-02-2022
Karakteristik produk Karakteristik produk Yunani 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Yunani 18-09-2014
Selebaran informasi Selebaran informasi Prancis 18-02-2022
Karakteristik produk Karakteristik produk Prancis 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Prancis 18-09-2014
Selebaran informasi Selebaran informasi Italia 18-02-2022
Karakteristik produk Karakteristik produk Italia 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Italia 18-09-2014
Selebaran informasi Selebaran informasi Latvi 18-02-2022
Karakteristik produk Karakteristik produk Latvi 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Latvi 18-09-2014
Selebaran informasi Selebaran informasi Lituavi 18-02-2022
Karakteristik produk Karakteristik produk Lituavi 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Lituavi 18-09-2014
Selebaran informasi Selebaran informasi Hungaria 18-02-2022
Karakteristik produk Karakteristik produk Hungaria 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Hungaria 18-09-2014
Selebaran informasi Selebaran informasi Malta 18-02-2022
Karakteristik produk Karakteristik produk Malta 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Malta 18-09-2014
Selebaran informasi Selebaran informasi Belanda 18-02-2022
Karakteristik produk Karakteristik produk Belanda 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Belanda 18-09-2014
Selebaran informasi Selebaran informasi Polski 18-02-2022
Karakteristik produk Karakteristik produk Polski 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Polski 18-09-2014
Selebaran informasi Selebaran informasi Portugis 18-02-2022
Karakteristik produk Karakteristik produk Portugis 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Portugis 18-09-2014
Selebaran informasi Selebaran informasi Rumania 18-02-2022
Karakteristik produk Karakteristik produk Rumania 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Rumania 18-09-2014
Selebaran informasi Selebaran informasi Slovak 18-02-2022
Karakteristik produk Karakteristik produk Slovak 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Slovak 18-09-2014
Selebaran informasi Selebaran informasi Sloven 18-02-2022
Karakteristik produk Karakteristik produk Sloven 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Sloven 18-09-2014
Selebaran informasi Selebaran informasi Suomi 18-02-2022
Karakteristik produk Karakteristik produk Suomi 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Suomi 18-09-2014
Selebaran informasi Selebaran informasi Swedia 18-02-2022
Karakteristik produk Karakteristik produk Swedia 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Swedia 18-09-2014
Selebaran informasi Selebaran informasi Norwegia 18-02-2022
Karakteristik produk Karakteristik produk Norwegia 18-02-2022
Selebaran informasi Selebaran informasi Islandia 18-02-2022
Karakteristik produk Karakteristik produk Islandia 18-02-2022
Selebaran informasi Selebaran informasi Kroasia 18-02-2022
Karakteristik produk Karakteristik produk Kroasia 18-02-2022
Laporan Penilaian publik Laporan Penilaian publik Kroasia 18-09-2014

Peringatan pencarian terkait dengan produk ini